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http://dx.doi.org/10.1016/j.pedneo.2Background: In Taiwan, the incidence of congenital heart diseases (CHDs) and severe CHDs was
13.08 and 1.51 per 1000 live births, respectively. This study further elucidates the prevalence
and mortality of pediatric CHD patients in Taiwan.
Methods: From the National Health Insurance database 2000e2010, we retrieved the data of
CHD patients (aged 0e18 years). Mortality data were obtained from the national death statis-
tics.
Results: In total, 45,119 pediatric CHD patients were identified, given the prevalence at 918.0
per 100,000 (107.1 for severe CHD and 853.8 for simple CHD). Ventricular septal defect, ostium
secundum-type atrial septal defect, patent ductus arteriosus, pulmonary stenosis, and
tetralogy of Fallot were the five most frequently diagnosed CHDs. In those aged 0e6 years,
the prevalence was 1233.7 per 100,000 (123.5 for severe CHD and 1149.6 for simple CHD).
The age-specific prevalence of both simple and severe CHDs declined rapidly after the age
of 10 years. From the death registry, we noted that more than 90% of CHD-related deaths
occurred before the age of 5 years. The probability of cardiac death in CHD patients duringof Pediatrics, National Taiwan University Hospital, Number 7, Chung-Shen South Road, Taipei 100,
(M.-H. Wu).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
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114 S.-J. Yeh et alinfancy was 4.5%, with the cumulative probability reaching 5.44%, 5.68%, and 6.04% by the
ages of 5, 10, and 20 years, respectively.
Conclusion: Because most CHD deaths occurred within the first 5 years of life (mainly during
infancy), the relatively low prevalence of CHDs in the population aged 0e18 years (918/
100,000; 74% for those between 0 years and 6 years of age) and the rapid decline in the
age-specific prevalence of CHD after the age of 10 years was attributed to noncompliance
of the children to medical follow-up after they began schooling.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Congenital heart disease (CHD) is a major concern in
pediatric health care and has a significant impact on infant
morbidity and mortality worldwide.1e3 Recent advances in
fetal diagnosis and postnatal cardiac intervention may
modify the CHD spectrum and subsequent medical
needs.4e7 The incidence of CHD varies between geographic
regions, and this variation has been attributed to the
number of patients with ventricular septal defects (VSD).8
The reported incidence of CHD among infants ranges from
four to 12 per 1000 live births and is estimated to be
approximately 10 per 1000 live births.5,9 A national pop-
ulation study conducted from 2000 to 2006 in Taiwan
showed that the incidence of CHD was 13.08 per 1000 live
births, with incidences of severe CHDs and simple CHDs at
1.51 and 11.67 per 1000 live births, respectively.10 The
reported prevalence of CHD varies because of differences
in the length of follow-up periods, as well as methods of
target population selection and case detection.2,5,11
Several multistage surveys have been conducted in
school-aged children in Taiwan12,13; the prevalence of CHD
ranged from 2.4 to 6.04 per 1000 children.12,13 The
discrepancy between the incidence and prevalence data
may be attributed to disease-related deaths and case
identification criteria, as set by the study methods. A
population-based study using a registry database may avoid
referral and diagnostic bias caused by geographic regional
variations and small sample sizes. The National Health
Insurance (NHI) is managed by the Bureau of National
Health Insurance, Department of Health. Since 1995, more
than 98% of Taiwanese nationals have been obligated by law
to join the government-run, single-payer NHI program.14
The Taiwan National Department of Health established
a national mortality database, which includes data on age-
specific mortality and causes of death. These national
databases serve as ideal resources for nationwide epide-
miological studies. Using these databases, we investigated
the overall and age-specific prevalence of CHD and CHD
subtypes. The probability of death from CHD was estimated
in order to elucidate its impact on disease prevalence.
2. Methods
2.1. NHI database
Health care records for the period between January 1, 2000
and December 31, 2010, were retrieved for analysis. Welimited our record retrieval to the birth cohort between
1992 and 2010. The completely computerized NHI database
consists of health records from each medical visit,
a scrambled identification number, and information
including the patient’s date of birth, gender, date of
admission or outpatient department visits, and reimburse-
ment. Patients diagnosed with any type of CHD (according
to the International Classification of Diseases, Ninth Revi-
sion, Clinical Modification [ICD-9-CM] code) were selected.
To avoid errors caused by incorrect tentative diagnoses,
insignificant asymptomatic CHD, and miscoding, we defined
prevalent CHD patients as those hospitalized with CHD as
the major disease or those who visited the outpatient
department with a major diagnosis of CHD consistently at
least three times within the study period. The CHD was
further classified as “simple” or “severe” based on the
diagnostic code (Table 1).102.2. Age-specific prevalence
The gender-specific population sizes by a single year of age
were obtained from the Statistical Yearbook of Interior,
Department of Statistics, Ministry of the Interior.15 In 2010,
a total of 4,915,037 children between 0 years and 18 years
made up the denominator used for calculating prevalence
and age-specific prevalence.2.3. Death statistics
The number of deaths from CHD (ICD 10, Q20eQ28) and
all causes were available from the Death Statistics for
2008 and 2009 compiled by the Department of Health.16
For calculating age-specific CHD mortality, the pop-
ulation size obtained in 2008 and 2009 were used as the
denominator. We constructed a hypothetic birth cohort of
100,000 newborns with CHD incidence at 1308 per
100,00010 and calculated the age-specific mortality for
CHD and for all other causes from the death statistics
data 2008e2009. We estimated the number of CHD
deaths, the number of deaths from other causes, and the
number of patients alive after considering the competing
risks in each age strata. We divided the number of CHD
deaths by the number of patients at risk of each age
strata to obtain age-specific estimates of death proba-
bility from CHD. The cumulative death probability from
CHD was defined as the cumulative number of CHD deaths
divided by 1308.
Table 1 CHD disease-specific prevalence rate (per 100,000) and test for gender predominance.
ICD-9-CM
code
Disease Severe (S)/
Simple (E)
Prevalence (105) p Prevalence (105) for children
of 0e6 years old (95% CI)Total Male Female
745 Bulbus cordis anomalies and anomalies
of cardiac septal closure (excluding
745.0, 745.1, 745.2, 745.3, 745.4, 745.5,
745.6)
E 24.0 22.5 25.6 0.0265 21.3 (19.1e23.9)
745.0 Common truncus S 7.3 7.0 7.7 0.6500 6.0 (4.8e7.4)
745.1 Transposition of great arteries (including
745.10, but excluding 745.11, 745.12)
S 15.5 19.8 10.9 <0.0001 18.7 (16.5e21.1)
745.11 Double outlet right ventricle S 9.5 10.1 8.9 0.1517 13.7 (11.9e15.8)
745.12 Corrected transposition of great arteries S 1.9 2.2 1.5 0.0741 2.5 (1.8e3.5)
745.2 Tetralogy of Fallot S 51.4 55.9 46.5 <0.0001 54.9 (51.1e58.9)
745.3 Common ventricle S 6.5 7.0 6.0 0.1573 6.5 (5.3e8.0)
745.4 Ventricular septal defect E 329.9 316.2 344.8 <0.0001 426.1 (415.4e437.1)
745.5 Ostium secundum-type atrial septal
defect
E 318.0 277.9 361.5 <0.0001 477.8 (466.5e489.4)
745.6 Endocardial cushion defect S 15.6 13.1 18.3 <0.0001 16.0 (14.1e18.3)
746.0 Pulmonary stenosis E 79.3 76.0 82.8 0.0075 94.4 (89.5e99.7)
746.1 Tricuspid atresia or stenosis S 3.5 4.1 2.9 0.0363 4.2 (3.2e5.4)
746.2 Congenital Ebstein’s anomaly E 3.7 3.1 4.4 0.0234 3.2 (2.4e4.3)
746.3 Aortic stenosis E 10.1 12.4 7.6 <0.0001 8.2 (6.8e9.8)
746.4 Congenital insufficiency of aortic valve E 3.0 3.5 2.5 0.0442 1.2 (0.8e2.0)
746.5 Congenital mitral stenosis S 1.4 1.3 1.5 0.6355 1.6 (1.0e2.4)
746.6 Congenital mitral insufficiency E 10.9 8.4 13.7 <0.0001 6.1 (4.9e7.6)
746.7 Hypoplastic left heart syndrome S 3.1 3.0 3.2 0.6586 5.1 (4.0e6.4)
746.81 Subaortic stenosis E 1.2 1.2 1.2 0.9509 1.4 (0.9e2.1)
746.82 Cor triatriatum E 1.2 1.1 1.4 0.3980 1.2 (0.8e2.0)
746.83 Infundibular pulmonic stenosis E 4.4 4.4 4.3 0.9513 5.3 (4.2e6.7)
747.0 Patent ductus arteriosus E 129.5 97.1 164.7 <0.0001 153.4 (147.0e160.0)
747.1 Coarctation of aorta E 21.4 22.4 20.3 0.1140 32.3 (29.5e35.5)
747.3 Anomalies of pulmonary artery E 45.5 44.4 46.7 0.2429 51.2 (47.6e55.1)
747.41 Total anomalous pulmonary venous
connection
S 7.4 7.8 7.1 0.3603 11.5 (9.8e13.4)
747.42 Partial anomalous pulmonary venous
connection
E 2.4 2.0 2.7 0.1168 2.9 (2.2e4.0)
Subtotal of severe CHD 107.1 114.0 99.7 <0.0001 123.5 (117.8e129.5)
Subtotal of simple CHD 853.8 770.3 944.8 <0.0001 1149.6 (1132.0e1167.4)
Total 918.0 839.7 1003.2 <0.0001 1233.7 (1215.5e1252.1)
A p value <0.002 was defined as significant with Bonferroni correction for multiple comparisons.
CHD Z congenital heart disease.
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Figure 1 Age-specific prevalence of total, simple, and
severe congenital heart diseases (CHDs) (per 100,000 children).
116 S.-J. Yeh et al2.4. Statistical analyses
We used the SAS software (SAS, Cary, NC, USA) for statis-
tical analyses. The overall and age-specific prevalence of
each CHD subtype were calculated. The age-specific and
gender-specific prevalence rates were estimated based on
the age of prevalent patients in 2010. We estimated prev-
alence and its 95% confidence intervals (CI) for each diag-
nostic code using PROC GENMOD with binomial distribution.
All tests were two-sided. A statistically significant p value
of <0.002 was defined, after including Bonferroni correc-
tion for multiple comparisons.
Age-specific mortality and overall mortality due to CHD
were calculated. The CHD mortality fraction was obtained
by dividing the number of patients who died from CHD by
the total number of deaths.
3. Results
A total of 45,119 prevalent patients who fulfilled the
inclusion criteria were identified.
3.1. Prevalence of CHD in pediatric populations
The overall prevalence of pediatric CHD per 100,000 chil-
dren was 918.0 (95% CI, 909.6e926.4), and the prevalence
of simple CHD and severe CHD was 853.8 (95% CI,
845.7e862.0) and 107.1 (95% CI, 104.3e110.1), respectively
(Table 1). Severe CHD represented 11.6% of all CHD cases.
The overall prevalence was lower than the summation of
the simple CHD and severe CHD because of the coexistence
of the two CHD types in the same patient. The most
common diseases, in descending order, were VSD (329.9/
100,000), ostium secundum-type atrial septal defect (ASDII;
318.0/100,000), patent ductus arteriosus (PDA; 129.5/
100,000), pulmonary stenosis (PS; 79.3/100,000), tetralogy
of Fallot (TOF; 51.4/100,000), coarctation of aorta (21.4/
100,000), endocardial cushion defect (15.6/100,000), and
transposition of great arteries (15.5/100,000) (Table 1).
These disorders accounted for 35.9%, 34.6%, 14.1%, 8.6%,
5.6%, 2.3%, 1.7%, and 1.7% of the total CHD cases,
respectively.
3.2. Gender preference
Although the prevalence of transposition of great arteries
(19.8 vs. 10.9), TOF (55.9 vs. 46.5), and aortic stenosis (12.4
vs. 7.6) was higher in boys than in girls, the prevalence of
VSD (344.8 vs. 316.2), ASDII (365.1 vs. 277.9), PDA (164.7 vs.
97.1), and endocardial cushion defect (18.3 vs. 13.1) was
higher in girls than in boys (Table 1). Moreover, both simple
and total CHDs were more prevalent in girls than in boys,
and severe CHD was more prevalent in boys.
3.3. Age-specific prevalence in 2010
During infancy, an upward trend was observed for age-
specific prevalence of total CHD that was maintained until
the age of 3 years, followed by a plateau at 3e10 years. The
prevalence rapidly declined to 516.5 per 100,000 children,who reached the age of 14 years, during the following
4 years, i.e., approximately 35.2% of its peak value. The
prevalence after the age of 14 years decreased further until
adulthood, but at a slower rate. The age-specific preva-
lence of CHD in 18-year-old individuals was 330.8 per
100,000, approximately 22.5% of the peak value (Figure 1).
The prevalence of simple CHD and severe CHD showed the
same pattern as total CHD, i.e., a decrease after the age of
10 years. The prevalence of severe CHD decreased to 72.0
at 14 years of age, i.e., approximately 41.8% of its peak
value, and further decreased at a slower rate to 53.2 per
100,000 at the age of 18 years, approximately 30.8% of the
peak prevalence (Figure 1).
Because the age-specific prevalence of CHD decreased
significantly after the age of 10 years, the prevalence of
CHD in preschool children aged 0e6 years was also exam-
ined (Table 1). In the age group of 6e10 years, the preva-
lence of CHD was 1233.7 per 100,000, i.e., 1149.6 for
simple CHD and 123.5 for severe CHD. Severe CHD repre-
sented 10% of all CHD cases. We found that ASDII (477.8 per
100,000 children) was the most common CHD in this age
group, followed by VSD (426.1 per 100,000), PDA (153.4 per
100,000), PS (94.4 per 100,000), and TOF (54.9 per 100,000)
(Table 1).
3.4. Mortality from CHD in pediatric populations
To elucidate the impact of mortality on disease prevalence,
the CHD-specific mortality rate was calculated from the
values obtained from the database of Death Statistics in
Taiwan. The CHD-specific mortality was 12.9 per 100,000 in
children aged 0e5 years; this decreased to 2.7 per 100,000
in the population aged 0e20 years (Table 2). The preva-
lence of age-specific CHD-related mortality was the highest
during infancy (58.8 per 100,000) and declined to 6.2, 2.4,
and <1 in children aged 1e2, 2e3, and 3e4 years,
respectively. More than 90% (137/157 in 2008 and 124/132
in 2009) of pediatric CHD-related deaths occurred within
the first 5 years of life. Among the all-cause mortality, the
CHD mortality fraction accounted for 11.7% and 6.6% in
children aged 0e5 years and 0e20 years, respectively. For
each age group, the highest fraction was found in children
aged 0e1 years and 1e2 years (13% deaths in both age
Table 2 The number of deaths from all causes and congenital cardiac anomalies (ICD-10 death codes Q20eQ28) in 2008e2009.
Age (y) Number of deaths CHD
mortality
(105)
Mortality
fraction
from CHD*(%)
In an assumed birth cohort
All cause CHD cause Death
probability
from CHDy (%)
Cumulative death
probability from
CHD cause (%)
Total Male Female
0e1 1675 218 108 110 58.8 13.0 4.50 4.50
2 193 25 9 16 6.2 13.0 0.54 5.05
3 149 10 3 7 2.4 6.7 0.22 5.26
4 115 2 1 1 0.5 1.7 0.04 5.31
5 100 6 2 4 1.4 6.0 0.13 5.44
6e10 432 11 2 9 0.4 2.5 0.24 5.68
11e15 467 6 4 2 0.2 1.3 0.13 5.81
16e20 1242 11 6 5 0.6 0.9 0.24 6.04
0e5 2232 261 123 138 12.9 11.7
0e20 4373 289 135 154 2.7 6.6
CHD Z congenital heart disease.
* Mortality fraction from CHD cause is a percentage that denotes the number of CHD-related deaths divided by the number of deaths
from all causes.
y Death probability from CHD cause was derived by assuming a cohort with a CHD incidence of 1308 per 100,000 and competing risk of
death from other causes.
Pediatric congenital heart disease in Taiwan 117groups). The probability of cardiac death from CHD was the
highest during infancy, with a probability of 4.5% that
rapidly decreased to 0.54% in children aged 1e2 years and
0.22% in children aged 2e3 years. The probability was quite
low after the age of 5 years. The cumulative probability of
cardiac death by the ages of 5, 10, 15, and 20 years was
5.44%, 5.68%, 5.81%, and 6.04%, respectively.4. Discussion
For studying congenital anomalies, both incidence and
prevalence are investigated but represent different attri-
butes. Incidence reflects the genetic variation or racial
differences involved in diseases, and prevalence reflects
the incidence, mortality, and duration of the disease, as
well as the disease burden for the society in which it
occurs. Although CHD prevalence should be close to its
incidence, prevalence may be lower after accounting for
mortality and patients lost to follow-up. Based on the
information obtained from our national databases, the
following two main findings were observed in the present
study: (1) the prevalence of pediatric CHD patients who
required/received medical care was 918 per 100,000, with
a rapid decline after the age of 10 years; and (2) the
cumulative probability of death by the time the children
were of the age of 10 years and 15 years was 5.68% and
5.81%, respectively. This decline in age-specific prevalence
after the age of 10 years is attributed to poor compliance of
older children to medical follow-ups rather than to
mortality.
The most common types of CHDs were VSD, ASDII, PDA,
PS, and TOF, but the incidence and prevalence differed for
each CHD group.9 The prevalent patients had a higher
proportion of VSD (35.9% vs. 30.7%), ASDII (34.6% vs. 24.7%),
and TOF (5.6% vs. 4.8%) than the neonatal cohort.10 This
difference might be explained by the longer natural history
and good survival rate after intervention for these CHDs.9However, the proportions of PDA (14.1% vs. 15.4%) and PS
(8.6% vs. 9.3%) were high in the neonatal cohort. High
spontaneous remission rates and successful interventions at
a young age might be the reason for the decreased
proportion of both types of CHD in subsequent follow-ups.
As shown in Table 1, although the prevalence of CHD in
children aged 0e6 years was found to be 1233 per 100,000
[similar to total CHD incidence (1308 per 100,000)10], the
overall prevalence of CHDs in children aged 0e18 years was
only 918 per 100,000 (i.e., 70.1% of CHD incidence and
74.5% of CHD prevalence in the population aged 0e6 years).
Age-specific prevalence decreased dramatically after the
age of 10 years. Less than 30% of patients complied with
regular cardiac follow-ups up to the age of 18 years,
regardless of whether they had simple or severe CHD. Such
a change in age-specific prevalence of CHD cannot be
explained by the natural or unnatural course of the disease,
because the cumulative probability of death in CHD
patients from birth to 5, 10, 15, and 20 years of age was
only 5.44%, 5.68%, 5.81%, and 6.04%, respectively. In
addition, there are 19 medical centers in Taiwan providing
pediatric cardiac programs under almost full NHI coverage;
medical access for CHD care is easy. Therefore, the lack of
willingness to attend continual cardiac follow-up after
entering school seems to be the major reason for the
decline in age-specific prevalence. Similar trends have
been observed in previous longitudinal follow-up stud-
ies.17e19 Mackie et al19 reported that the compliance rate
for continual cardiac follow-up was only 72% at 6e12 years
and 53% at 13e17 years in CHD patients who were diag-
nosed before the age of 6 years.19 Male patients and those
with less severe CHD are less likely to pursue follow-up
care.19 Despite this factor, the noncompliance rate is very
high in Taiwan, the reasons for which should be investi-
gated in the future. Such low adherence might cause
unnecessary complications such as bacterial endocarditis,
hyperviscosity syndrome, and iron deficiency anemia; these
complications result in increased morbidity, subsequent
118 S.-J. Yeh et almortality, and disease burden in children with CHD as they
grow up.
Infant mortality in Taiwan is similar to that in the United
States.9,13 Of all infant deaths, congenital malformations,
deformations, and chromosomal anomalies (ICD 10,
Q00eQ99) are the leading causes in both the United States
and Taiwan, accounting for 19.9% (United States) and 22.8%
(Taiwan).20 CHD-related infant mortality in Taiwan was
approximately 58.8 per 100,000, which was higher than that
in the United States (41.46 per 100,000).3 The difference in
CHD-related infant mortality between these two countries
in the age group of 1e5 years was still significant (2.59 and
1.38 per 100,000 in Taiwan and the United States, respec-
tively). In the age group of 6e15 (17) years, the differences
became insignificant (0.30 vs. 0.41 per 100,000). Overall,
the CHD-related mortality rate in U.S. infants was only 71%
of the Taiwanese rate; in preschool children, it was only
53%. Because the incidence of severe CHD is approximately
1.5/1000 in both Taiwan and the United States,9 worse
outcomes of CHD infants and children in Taiwan should not
be related to disease severity per se. This should be clari-
fied by further outcome-based studies.
In summary, the prevalence of CHD in pediatric patients
who required/received medical care in Taiwan was 918 per
100,000 for individuals aged 0e18 years and 1233 per
100,000 for children aged 0e6 years. Because most (i.e.,
greater than 90%) of CHD deaths occurred within the first 5
years of life (mainly during infancy), the decline in the age-
specific prevalence of CHD after the age of 10 years was
attributed to noncompliance to medical follow-ups because
of the interference of schooling activity. Even in countries
with a national health insurance system and easy medical
access, poor compliance to medical follow-ups is a common
phenomenon in CHD children of school-going age.
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